18
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T11467 | GSK-3β inhibitor 1 | GSK-3 | |
GSK-3β inhibitor 1 is an inhibitor of GSK-3β( IC50 of 4.9 nM) and demonstrates high antidiabetic efficacy. | |||
T9178 | (E/Z)-GSK-3β inhibitor 1 | GSK-3β inhibitor 1 | GSK-3 |
(E/Z)-GSK-3β inhibitor 1 is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy. | |||
T64366 | GSK3-IN-4 | GSK-3 | |
GSK3-IN-4 is a GSK-3 inhibitor with IC50 of 0.101-1 μM of GSK-3α and GSK-3β in Calipe Assay. | |||
T61809 | GSK-3β inhibitor 11 | GSK-3 | |
GSK-3β inhibitor 11 (compound 21) is a potent inhibitor of glycogen synthase kinase-3β (GSK-3β) with an inhibitory concentration (IC50) of 10.02 μM. This compound demonstrates potential utility in the field of neurodegen... | |||
T6358 | 1-Azakenpaullone | azakenpaullone | GSK-3 |
1-Azakenpaullone (azakenpaullone) is a potent and selective GSK-3β inhibitor with IC50 of 18 nM, >100-fold selectivity over CDK1/cyclin B and CDK5/p25. | |||
T61360 | ARN25068 | GSK-3 , DYRK , Microtubule Associated , Src | |
ARN25068 is a potent inhibitor of GSK-3β, FYN, and DYRK1A protein kinases, exerting its activity in the sub-micromolar range. This compound effectively addresses tau hyperphosphorylation [1]. | |||
T14613 | BIP-135 | GSK-3 | |
BIP-135 is a potent and selective ATP-competitive GSK-3 inhibitor. With IC50s of 16 nM and 21 nM for GSK-3α and GSK-3β, respectively. BIP 135 exhibits neuroprotective effect[1]. | |||
T6187 | TDZD-8 | GSK-3β Inhibitor I,NP 01139 | GSK-3 |
TDZD-8 (NP 01139) is an inhibitor of GSK-3β, with an IC50 of 2 μM; minimal inhibitory effect observed on CDK1, casein kinase II, PKA and PKC. | |||
T2378 | RGB-286638 free base | GSK-3 , MEK , JAK , CDK | |
RGB-286638 free base is a novel CDK inhibitor with IC50s of 1 nM/2 nM/3 nM/4 nM/5 nM for cyclin T1-CDK9/cyclin B1-CDK1/cyclin E-CDK2/cyclin D1-CDK4/cyclin E-CDK3/p35-CDK5 respectively; less potent against cyclin H-CDK7 a... | |||
T22157 | TCS 2002 | ||
GSK-3β inhibitor 9 (Compound 9b) is a highly selective, orally bioavailable and potent GSK-3β inhibitor with the IC 50 of 35 nM. GSK-3β inhibitor 9 exhibits good pharmacokinetic profiles including favorable BBB penetrati... | |||
T64143 | AChE/GSK-3β-IN-1 | ||
AChE/GSK-3β-IN-1 is a potent dual AChE/GSK-3β inhibitor that crosses the blood-brain barrier and acts on hAChE (IC50: 1.2 nM), hBChE (IC50: 149.8 nM) and hGSK-3β (IC50: 22.4 nM). AChE/GSK-3β-IN-1 is able to occupy the AT... | |||
T61804 | GSK-3β inhibitor 6 | ||
GSK-3β inhibitor 6 is a highly potent inhibitor of GSK-3β, with an IC50 value of 24.4 μM. It demonstrates significant enhancement of hepatocyte glucose uptake (38%). This compound holds great potential for studying vario... | |||
T24969 | 18BIOder | 18 BIOder,18-BIOder | |
18BIOder is a neuroprotective inhibitor of GSK-3β, highly selectively inhibiting HIV-1. It is the second generation derivative of 6BIO. | |||
T60748 | ZDWX-25 | ||
ZDWX-25 is a highly potent dual inhibitor of GSK-3β and DYRK1A that possesses significant cytotoxic activities towards SH-SY5Y and HL-7702 cells. ZDWX-25 can be used for Alzheimer's disease research with an IC 50 value o... | |||
T78874 | GSK-3β inhibitor 15 | ||
GSK-3β inhibitor 15 (Compound 54), with an IC50 of 3.4 nM, effectively suppresses Aβ 1-42-induced phosphorylation of GSK-3β and tau protein, as well as LPS-induced iNOS expression. It demonstrates neuroprotective propert... | |||
T68855 | Hymenialdisine Analogue #1 | ||
Hymenialdisine Analogue #1 is the indole derivative of Hymenialdisine, a potent inhibitor of a variety of kinases including MEK-1, GSK-3Β, and CKI. It also exhibits inhibition of the G2 cell cycle checkpoint at the micro... | |||
T35560 | SAR502250 | ||
SAR502250 is a potent, selective, ATP-competitive, orally active, and brain-penetrant GSK3 inhibitor with a human GSK-3β IC50 value of 12 nM. It exhibits antidepressant-like activity and is being researched for potential... | |||
T73196 | RGB-286638 | ||
RGB-286638 is a multi-target CDK inhibitor that effectively hampers the kinase activity of a range of cyclin-CDK complexes, including cyclin T1-CDK9 (IC50 = 1 nM), cyclin B1-CDK1 (IC50 = 2 nM), cyclin E-CDK2 (IC50 = 3 nM... |